AEDV HIGHLIGHTS
27TH EADV CONGRESS
12-16 September 2018
PARIS, France
Psoriasis

Dra. Noemí Eirís Salvado
• Classic systemics
• Apremilast
• Fumaratos
• AntiTNF
  • Infliximab
  • Etanercept
  • Adalimumab
  • Certolizumab
• Biosimilars of antiTNF
• Anti-IL12/23
  • Ustekinumab
• Anti-IL 17
  • Bimekizumab
  • Ixekizumab
  • Secukinumab
  • Brodalumab
• Anti-IL 23
  • Mirikizumab
  • Tildrakizumab
  • Risankizumab
  • Guselkumab
• Anti PDE4
  • Apremilast
Sistemic treatments

- Adding methotrexate to adalimumab therapy improved treatment efficacy and quality of life in psoriasis patients → K. Papp, et al.

- Trough (C0) and 2-hour post-dose (C2) cyclosporine monitoring in patients with moderate-to-severe psoriasis → Herrero-Moyano, et al. Hospital Universitario de La Princesa
  - Significant correlation between C2 concentrations and decrease of PASI at w16, particularly when CsA C2 levels were higher than 1000 ng/ml.
Apremilast

• Oral communication:

  • **FC06.09 Apremilast for the Treatment of Oral Ulcers in Behcet's Syndrome: A Phase III Randomized, Double-Blind, Placebo-Controlled Study (RELIEF)**
    • Apremilast 30 mg BID over 12 weeks → 50% reduction in the mean number and pain of oral ulcers, 50% patients achieved complete resolution of oral ulcers. Safety profile similar as in Psoriasis patients

  • Poster: Pharmacokinetics and Safety of Apremilast in Pediatric Patients with moderate to severe plaque psoriasis. Results from a Phase 2 study → Paller et al.
    • <35 kg APR 20 mg/d, 35-70 kg APR BID, >70 kg APR 30 BID
    • Safety and efficacy profile similar to adults. Perhaps in children over 50 kg but <70kg APR30 daily would be more appropriate.
Fumarates

- FC06.05 Clinical response of fumaric acid esters in psoriasis: Registry data from 1,409 patients in Germany
Certolizumab

- Efficacy of Certolizumab Pegol in Psoriasis Patients Failing to Respond to Etanercept: Results from an ongoing, Phase 3 study.
  - Patients with moderate to severe PSO who did not achieve a PASI 50 response after 12 weeks of ETN therapy showed improvements of their clinical disease after switching to CZP 400 mg Q2W.
  - Over half of patients achieved PASI90 after 32 weeks of CZP treatment.

- Durability of Response in patients with chronic plaque psoriasis treated with Certolizumab Pegol after 48 weeks: pooling of CIMPASI-1, CIMPASI-2 and CIMPACT phase III studies
  - In those who achieve response, it tends to persist over time.
• Identification of clinical and biomarker parameters associated with long-term maintenance PASI 90 response after withdrawal of Guselkumab treatment in Psoriasis → Liu et al.
  • Shorter disease duration, lower BMI, lower levels of serum IL17F and MIPB1 at baseline, achieving PASI100 or IGA 0 at w 28 and higher drug concentration at w28.

• No reactivation of TBC in LTBI treated patients or TBC negative patients at w100 on Guselkumab treatment.
Genetics and basic findings

• Histone modifications associated with biologic drug response in moderate-to-severe psoriasis → Dauden, et al.

• Genetic, experimental and in vitro evidence of the relevant role of the lymphocitic receptor CD6 in psoriasis → Juliá, et al.

• Pharmacogenetic analysis of NF-KB pathway gen variants: prediction response to anti TNF therapy in a Spanish psoriatic cohort → Gonzalez-Lara, et al.

• Intestinal barrier integrity in psoriasis → Sikora, et al. Poland
Various themes

- Optimization strategies (escalation and reduction of doses) of biological therapies in moderate to severe psoriasis → Daudén, et al.
  - Evidence for starting dose reduction in patients reaching PASI90 or PASI lower than 3 in two consecutive visits. Well-controlled patients under reduced doses seem to have similar PASI75 results, safety and no shorter persistence than patients on standard dosing.

- Auditory system involvement in psoriatic patients: a pilot study → Borgia, et al. Italy
  - More pronounced hearing loss in psoriatic patients, perhaps due to metabolic syndrome on top of morpho-functional alterations.